Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm multicenter study of FCN-159 in recurrent or progressive low-grade glioma
CTR20213289Phase 2Completed
- Sponsor
- Fosun Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in glioma, sponsored by Fosun Pharma. Started Jul 2022; status: completed.
02
Drugs
luvometinib
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20213289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213289.